HK Stock Market Move | PEIJIA-B (09996) surged nearly 7% during trading, with strong expectations for the launch of a major product this year. Institutional investors believe that the company's performance is approaching a crucial turning point.

PEIJIA-B (09996) increased by nearly 7% in midday trading. As of the time of writing, it was up by 4.88% at HK$4.3, with a turnover of HK$1.9418 million. On the news front, China Securities Co., Ltd. previously pointed out that the company is expected to reach a key turning point in performance growth in 2026, with accelerated revenue growth and a full-year profit turnaround. The firm stated that with the commercialization and volume increase of the company's TaurusTrio backflow valve, as well as the potential approval for several heavyweight innovative products such as the third-generation TAVR product TaurusNXT and the GeminiOne mitral valve edge-to-edge repair backflow product within 2026, the company's product portfolio in the area of structural heart disease continues to enrich. Its technological leadership and long-term competitiveness will be further strengthened. In addition, Peijia Medical previously announced that its subsidiary Jiaqi Biology has entered into an exclusive distribution agreement with B. Braun Medical. According to the agreement, Jiaqi Biology has obtained the exclusive distribution rights for B. Braun Medical's product SeQuent Please CIS paclitaxel drug-coated intracranial balloon dilatation catheter in mainland China. The cooperation with B. Braun Medical further enriches the group's neurointerventional product portfolio and strengthens the group's strategic layout in the field of innovative intracranial intervention solutions.